4-Hydroxytamoxifen

Catalog No.S7827 Synonyms: Afimoxifene

4-Hydroxytamoxifen Chemical Structure

Molecular Weight(MW): 387.51

4-Hydroxytamoxifen is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.

Size Price Stock Quantity  
USD 117 In stock
USD 497 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 4 Publications

1 Customer Review

  • CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments.

    Oncogene, 2016, 36(16):2255-2264. 4-Hydroxytamoxifen purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description 4-Hydroxytamoxifen is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.
In vitro

4-OHT is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes[1]. 4-HT activates on-target modification frequency for intein-Cas9 variants [3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 cells NUHwU5VoWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3XBd2lvcGmkaYTpc44hd2ZiZYP0do9o\W5vc4TpcZVt[XSnZDDNR2YuPyClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OC53IH7N MnGxPVU1QDhzNx?=
MCF7 cells NFrldnNHfW6ldHnvckBie3OjeR?= NIXTPHZKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDNR2YuPyCkcnXhd5QhfHWvb4KgZ4VtdHNidYPpcochVUOILUegZZN{[XluIFnDOVA:QC53IH7N NHjQ[ZUyOjh{NUmzOS=>
MCF7 cells NGS5[YNRem:uaX\ldoF1cW:wIHHzd4F6 NUnwVoNqPzJiaB?= NGjWO3pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIV{fHKxZ3XuJJJm[2WydH;yJIRmeGWwZHXueEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xNFch|ryP NIDxPVgyQDh|NUG3Oi=>
MCF7 cells NVS3NVFUWHKxbHnm[ZJifGmxbjDhd5NigQ>? MoPrNlQhcA>? M1m4WmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB{NDDodpMh[nliTWTTJIF{e2G7LDDJR|UxRThwNTDuUS=> MoTHNVgzPzJ{NU[=
T47D:C:4:2 cells NFfFUHdHfW6ldHnvckBie3OjeR?= MU\Fd5Rzd2enbnnjJIFkfGm4aYT5JIF1KHerbHSgeJlx\SCHUjDhcJBp[SCneIDy[ZN{\WRiaX6gWFQ4TDqFOkS6NkBk\WyuczDjc4V5eHKnc4Ppcoch\XO2cn;n[Y4hemW|cH;ud4Uh\WynbXXueEBjgSCmdXXsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NGTGW2EzODN|NEO2PC=>
MDA-MB-231 cells MXfGeY5kfGmxbjDhd5NigQ>? NITqU3k{KGSjeYO= NWX5XpZNS3m2b4P0ZZRq[yCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IH3pZ5JwfGm2ZYKgZZN{[Xl? MmLuNlA2QTh3NUW=
PC3 cells MonnVJJwdGmoZYLheIlwdiCjc4PhfS=> NYe4eWhtPDhiaB?= M17QeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgZY5lem:pZX6gdoVk\XC2b4Kt[IVncWOrZX70JIh2dWGwIGDDN{Bk\WyuczDpcoN2[mG2ZXSge4l1cCByLk[gcm0hd2ZiZYP0doFlcW:uIHHu[EAxNjdibl2gc4YhfGW|dH;zeIVzd26nIHHmeIVzKDR6IHjyd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUeuOVg2PzhizszN MW[yNVUyOzJ5NR?=
DU145 cells MWXQdo9tcW[ncnH0bY9vKGG|c3H5 NYTZWXB3PDhiaB?= M4K1ZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgZY5lem:pZX6gdoVk\XC2b4Kt[IVncWOrZX70JIh2dWGwIFTVNVQ2KGOnbHzzJIlv[3WkYYTl[EB4cXSqIECuOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwNzDuUUBw\iC2ZYP0c5N1\XKxbnWgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NVAvPzF3MjFOwG0> NYPLUXdsOjF3MUOyO|U>
LNCAP cells NHrad3pRem:uaX\ldoF1cW:wIHHzd4F6 NVzL[3A1PDhiaB?= MmnzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOTlPBVEBk\WyuczDlfJBz\XO|aX7nJIFv\HKxZ3XuJJJm[2WydH;yJIlv[3WkYYTl[EB4cXSqIECuOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwNzDuUUBw\iC2ZYP0c5N1\XKxbnWgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9PE4{OTd4NDFOwG0> NYTuU3VROjF3MUOyO|U>
T47D cells M1vFTWN6fG:2b4jpZ4l1gSCjc4PhfS=> MYm1JIRigXN? MmfpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC1JIRigXNuIFnDOVA:OC5{MTFOwG0> M1fwc|I{QDZ2OUK4
MDA-MB-231 cells M2HEWHBzd2yrZnXyZZRqd25iYYPzZZk> NVfy[nFkOjRiaB?= MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xNE41KM7:TR?= NWPWc2ZGOjRzOEmwOVU>
MCF7 cells M4m0fWZ2dmO2aX;uJIF{e2G7 MWexNEDPxE1? MUC2JIg> M2\zenVxemWpdXzheIlwdiCxZjDFVoFteGijIIDyc5RmcW5ibHX2[Yx{KGmwIHj1cYFvKE2FRkegZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhPiCqcoOgZpkhX2W|dHXyckBjdG:2IH3leIhw\A>? NXnSNGtoOjR|M{K2N|A>
SKOV3 cells MY\GeY5kfGmxbjDhd5NigQ>? NGHz[G81QCCq NW\NO3BqSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJHNMV1Z|IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHAu\3BiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF04NjR4IN88US=> M2PVcVI1QTR4MUS1
MDA-MB-231 cells NGDIcXpHfW6ldHnvckBie3OjeR?= M3HsdFQ5KGh? MXjBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iRWKtdI9{cXSrdnWgUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTVwNDFOwG0> MljuNlQ6PDZzNEW=
MCF7 cells NVHPU4tvTnWwY4Tpc44h[XO|YYm= NVrOfmYxPDhiaB?= M1fIXWFvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDFVk1xd3OrdHn2[UBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUC9PU4zKM7:TR?= MVyyOFk1PjF2NR?=
MDA-MB-231 cells MnzHSpVv[3Srb36gZZN{[Xl? M37WUlQ5KGh? NUL0Xm1PSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNW6nZ3H0bZZmKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME22MlIh|ryP M{fad|I1QTR4MUS1
MCF7 cells MWnGeY5kfGmxbjDhd5NigQ>? MlLCNlUxKHSxIEWwNEBvVQ>? NGHQbGk2KGSjeYO= M{\vNWFvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDFVk1xd3OrdHn2[UBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh\XO2cnHkbY9tNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK1NEB1dyB3MECgcm0h[W[2ZYKgOUBl[Xm| NXv6OGVKOjR7NE[xOFU>
MCF7 cells M1zocmN6fG:2b4jpZ4l1gSCjc4PhfS=> MVi0PEBp MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUOuOkDPxE1? MWKyOVYyQDV7NR?=
DU145 cells NFT5VINRem:uaX\ldoF1cW:wIHHzd4F6 MVm3NkBp NXPvWGtlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OTVwMzFOwG0> MWeyOVk6OzJ4OR?=
african green monkey Vero cells NXfSfXVMWHKxbHnm[ZJifGmxbjDhd5NigQ>? MWK3NkBp NETiVIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUG1MlEh|ryP M4Dhb|I2QTl|Mk[5
BT-20 cells M1XpZnBzd2yrZnXyZZRqd25iYYPzZZk> MXLJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgdJJwdGmoZYLheIlwdiCxZjDCWE0zOCClZXzsd{BqdiCycnXz[Y5k\SCxZjDUVGUh[XRiMUDlMVUhVSClb37j[Y51emG2aX;u M3zYcVI4Pjl4OEG=
Ishikawa endometrial cells NW\tPFh2TnWwY4Tpc44h[XO|YYm= MoHERY51[WexbnnzeEBi[3Srdnn0fUBieyCrbnjpZol1cW:wIH;mJFEhdk1iMUetZoV1[S2nc4TyZYRqd2xic4TpcZVt[XSnZDDhcItidGmwZTDwbI9{eGijdHHz[UBqdmS3Y4Tpc44hcW5iSYPobYtif2FiZX7kc41mfHKrYXygZ4VtdHNuIFnDOVA:OC53MTFOwG0> M2[yPVE2OzhyMkC4
MCF-7-2a cells NWD4XJl7TnWwY4Tpc44h[XO|YYm= MX\Jcohq[mm2aX;uJI9nKGW|dILh[IlwdCCrbnT1Z4VlKGW|dILv[4VvKHKnY3XweI9zKHS{YX7zZ5JqeHSrb37hcEBi[3SrdnH0bY9vKGmwIF3DSk04NTKjIHPlcIx{NCCLQ{WwQVAvODB5IN88US=> NGX5V2wyOjZ5MkK0PS=>
Calu-1 cells M4PNNWZ2dmO2aX;uJIF{e2G7 NH76dmc{OCCvaX7z NWTFOJdlUW6qaXLpeIlwdiCxZjDQUGQyKGmwIHj1cYFvKEOjbIWtNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCyaH;zdIhifGmmeXzieZRidm:uLWvkPX0heHKxZIXjeIlwdiCjZoTldkA{OCCvaX7zJIJ6KG2jc4Ogd5Bm[3S{b33leJJq[yCjbnHsfZNqeyxiSVO1NF01NjhizszN NIO5OXQyQTF|Nkm3OS=>
MCF12A cells M{jkOXBzd2yrZnXyZZRqd25iYYPzZZk> NGrvVm41QCCq NETwbWRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIV{fHKxZ3XuJJJm[2WydH;yMYRm\mmlaXXueEBpfW2jbjDNR2YyOkFiY3XscJMhcW6ldXLheIVlKHerdHigNE4xODNibl2gc4Yh\XO2cnHkbY9tKGGwZDCwMlAyKG6PIH;mJJRme3Sxc4Tldo9v\SCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTDpckBxemW|ZX7j[UBw\iB3JTDm[ZRidCCkb4\pcoUhe2W{dX2sJGdKPTB;Mz6zNVE{OSEQvF2= NHrjOYIzOTVzM{K3OS=>
MCF7:WS8 cells NHLscolHfW6ldHnvckBie3OjeR?= MkfHRYN1cX[jdHnvckBw\iCqdX3hckBGWiCrbjDoeY1idiCPQ1[3PndUQCClZXzsd{BmgHC{ZYPzbY5oKGW|dILv[4VvKHKnc4DvcpNqfmViZXzlcYVvfCCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> NGXLeZIzODN|NEO2PC=>
HEK293 cell NF\TNFlHfW6ldHnvckBie3OjeR?= NYC5Wow4OzBibXnudy=> M4XhZ2lvcGmkaYTpc44hd2ZiR1\QMZRi\2enZDDoeY1idiCSTFSyJIV5eHKnc4Pl[EBqdiCqdX3hckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4heGixc4DoZZRq\HmuYoX0ZY5wdC2dZEndJJBzd2S3Y4Tpc44h[W[2ZYKgN|AhdWmwczDifUBu[XO|IIPw[YN1em:vZYTybYMh[W6jbInzbZMtKEmFNUC9NE4xPDRizszN M4fwUFE6OTN4OUe1
MCF12A cells NXP6UZZmWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVnGS2lZPDhiaB?= MmDiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDld5Rzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iTVPGNVJCKGOnbHzzJIlv[3WkYYTl[EB4cXSqIECuNFYhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkC3JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kBn\XSjbDDic5ZqdmVic3XyeY0h[W6mIF71V4VzfW1uIFfJOVA:Oy56OUC0OUDPxE1? Ml:0NlE2OTN{N{W=
HEK293 cells NH;LRWZHfW6ldHnvckBie3OjeR?= NED4NpdC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIV{fHKxZ3XuJJJmdGG2ZXSgdoVk\XC2b4Kg[4FudWFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEeLNUC9NU4{PSEQvF2= Mn[1NlU{ODV4OEi=
rat GH3 cells M1fUO2Z2dmO2aX;uJIF{e2G7 M1\NRVQ5KGh? M3HkN2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWKgbY4hemG2IFfIN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJi\GmxbD3pcoR2[2WmIIDyc4xi[3SrbjDn[Y5mKGW6cILld5Nqd25iYYSgNVAoNTZiTTDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{ NGDqUmkzPDhyNUG5PS=>
MCF7:WS8 cells MnLVSpVv[3Srb36gZZN{[Xl? MYO0PEBp MVPB[49vcXO2IHHjeIl3cXS7IHH0JGVTKGmwIHj1cYFvKE2FRke6W3M5KGOnbHzzJIF{e2W|c3XkJIF{KEeURVKxJIdmdmViZYjwdoV{e2mxbjDheEAyOCdvNjDNJIFnfGW{IES4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN? NXvZOVRZOjR6MEWxPVk>
rat GH3 cells NI\FbJhHfW6ldHnvckBie3OjeR?= NH\scVg1QCCq M121N2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWKgbY4hemG2IFfIN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJi\GmxbD3pcoR2[2WmIIDyc4xi[3SrbjDn[Y5mKGW6cILld5Nqd25iYYSgNVAoNTFyIITvJFExLy14IF2gZYZ1\XJiNEigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>? NF;lUoMzPDhyNUG5PS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK / p-MEK / MEK1 / MEK2 / p21 / Cyclin D1 ; 

PubMed: 26163823     


LNCaP-Raf:ER cells were treated with increasing doses of 4-hydroxytamoxifen for 2 days. The bottom panel indicates densitometry of MEK1 and MEK2 signals. Data (mean ± standard error) are from two independent experiments. Pearson’s r = 0.823 for MEK1 and −0.673 for MEK2. 

26163823
Growth inhibition assay
Cell viability; 

PubMed: 26014809     


Dose-dependent effect of 4-hydroxytamoxifen on survival of T47D, MCF-7 and BT-474 cell lines after 96 h of treatment. Control samples were treated with appropriate concentrations of DMSO. Viability was assayed by MTT method.

26014809

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Adult Rat and Mouse Cardiac Myocytes
  • Concentrations: 0, 0.5, 1, 3, 5, and 10 µM
  • Incubation Time: 15-45 min
  • Method:

    For sarcomere length measurements, cells are covered in Tyrode’s containing 4OHT, allowed to reach 36 ± 1°C, and then stimulated at 0.2 Hz.


    (Only for Reference)
Animal Research:

[2]

- Collapse
  • Animal Models: Sprague-Dawley rats
  • Formulation: dissolved in 200 μl tricaprylin
  • Dosages: 21 mg/kg, 54 μmol/kg
  • Administration: oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 77 mg/mL (198.7 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 387.51
Formula

C26H29NO2

CAS No. 68392-35-8
Storage powder
in solvent
Synonyms Afimoxifene

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03199963 Terminated Drug: 4-OH tamoxifen|Drug: Placebo Mammographic Breast Density BHR Pharma LLC August 21 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Estrogen/progestogen Receptor Signaling Pathway Map

Related Estrogen/progestogen Receptor Products

Tags: buy 4-Hydroxytamoxifen | 4-Hydroxytamoxifen supplier | purchase 4-Hydroxytamoxifen | 4-Hydroxytamoxifen cost | 4-Hydroxytamoxifen manufacturer | order 4-Hydroxytamoxifen | 4-Hydroxytamoxifen distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID